Social Media Mythbusters: Exosomes in Skin Care

From viral skin care hacks to trendy treatment devices, social media is shaping the questions patients bring into the exam room every day. In Dermatology Times’ new weekly series, Social Media Mythbusters, we break down trending claims clinicians are hearing in practice—exploring the proposed mechanism, what the evidence shows (or doesn’t), and whether each trend holds up under scrutiny.

In this edition, we’re examining skin care products that feature exosomes.

Have a social media trend you’d like us to investigate next? Send us the social media myths your patients are asking about, and we may feature them in an upcoming edition. Connect with us on our social media or email us at [email protected].

The Trend

Exosomes could be one of the most scientifically legitimate-sounding trends this series has covered—and that is precisely what makes the gap between the underlying biology and the commercial claims worth an installment. Exosome biology is a real, actively researched area of cell biology with plausible regenerative mechanisms. What has happened commercially is that this legitimate research area has been marketed simultaneously in 2 very different product categories that patients (and some providers) frequently conflate: professionally administered, cell-derived exosome products used after microneedling, laser, or as injectables at med spas, and over-the-counter "exosome" serums sold directly to consumers for home use.

These 2 categories differ enormously in regulatory status, safety profile, and plausibility of actually delivering functional exosomes to the skin; differences that essentially never appear in the marketing for either one.

Dustin Portela, DO(@drdustinportela)

The Mechanism

Exosomes are extracellular vesicles roughly 30–150 nanometers in diameter, released by cells as part of normal paracrine signaling, carrying a cargo of proteins, lipids, and nucleic acids that can influence the behavior of recipient cells. In dermatology-relevant research, exosomes derived from mesenchymal stem cells and other sources have plausible mechanisms for skin-relevant effects: promoting extracellular matrix production, inhibiting matrix metalloproteinases, modulating local inflammation, and stimulating follicular activity—mechanisms with genuine relevance to photoaging, wound healing, scarring, and hair loss.¹ This mechanistic plausibility is real and is why the research area has attracted serious scientific attention, not just marketing interest.

In the US, no exosome-based product has received FDA approval for any dermatologic or aesthetic indication, and the FDA has been explicit and repeated in stating that products derived from human cells or tissues intended to treat a condition are regulated as unapproved drugs or biologics, regardless of how they are marketed. This matters clinically because it means professionally administered, cell-derived exosome products (the kind added to microneedling or laser treatments at many med spas) exist in a genuine regulatory gray zone with no standardized manufacturing oversight, and any product making a therapeutic claim is, by FDA's own framing, being marketed illegally.²

Over-the-counter topical "exosome" serums occupy a different, less scrutinized category: most are formulated as cosmetics rather than biologics, and many use plant-derived exosome-like nanovesicles (PENs) rather than human or mesenchymal stem cell-derived material—a meaningfully different product with its own (also largely preclinical) evidence base, but frequently marketed using imagery and language borrowed from the regenerative-medicine exosome literature.³

The Evidence

The clearest and most clinically important evidence in this installment is the safety data. In December 2019, the FDA issued a Public Safety Notification after multiple patients in Nebraska experienced serious adverse events following treatment with unapproved products marketed as containing exosomes, working jointly with the CDC and state health authorities to investigate.² Since that notification, FDA enforcement has escalated rather than resolved: warning letters have been issued to numerous manufacturers and clinics—including a documented 2023 warning letter and continued actions through 2024–2026—citing marketing of unapproved new drugs, distribution of unlicensed biological products, and failure to validate sterility procedures, with reported adverse events including severe infections, allergic reactions, and tumor formation. No exosome product has completed FDA's approval pathway to date, and the only legal route for therapeutic administration in the US is under a formal Investigational New Drug application.

On the efficacy side, 2 systematic reviews published earlier this year found positive associations between exosome-based treatments and outcomes including skin elasticity, hydration, and wrinkle depth, while both explicitly concluded that larger, standardized clinical trials are still needed before firm conclusions can be drawn.^4,5 A separate 2025 literature review characterized the existing evidence base as largely preclinical or early-phase, with inconsistent isolation and characterization methods across studies and variable sourcing that raises open questions about potency and safety comparability between products.¹ This puts exosomes well behind more established regenerative aesthetic modalities like platelet-rich plasma, which has multiple completed randomized controlled trials, and polynucleotides, which carry a more developed peer-reviewed evidence base and clearer regulatory standing in several markets.

For over-the-counter topical exosome products, the central open question is not just efficacy but basic feasibility: can intact skin actually absorb functional extracellular vesicles from a topically applied serum? Plant-derived exosome-like nanovesicles have shown some capacity for stratum corneum and follicular/appendageal-route penetration in porcine skin models, and in vitro work on plant-derived exosome extracts has demonstrated favorable effects on markers of barrier gene expression and inflammatory cytokines in cultured keratinocytes.⁶ This is genuinely interesting preclinical signal—but it is cell-culture and animal-model data, not clinical trial evidence in human skin, and it says little about what a patient applying a jar of serum to intact, unbroken facial skin is actually achieving. Overall, the framing of professionally administered exosome treatments as an approved, standardized, or clearly safe "next-generation" alternative to established regenerative treatments is not supported.

Firas Al-Niaimi, MD, MSc, MRCP, EBDV(@prof.firasalniaimi)

The Verdict

Is this a myth? Yes and no!

This is a case where "mythbusting" isn't about debunking the underlying biology. Exosome-mediated paracrine signaling is legitimate cell biology with plausible relevance to skin repair and regeneration. The problem is entirely on the product and regulatory side. For professionally administered, cell-derived exosome treatments, the combination of no FDA approvals, an active and escalating enforcement pattern, and a documented history of serious adverse events is a genuine clinical safety issue, not just a labeling technicality, and deserves to be communicated to patients as such.

For OTC topical serums, the more mundane problem is that the evidence for meaningful delivery through intact skin is thin and mostly preclinical, making inflated marketing claims the primary concern rather than any acute safety signal. These early systematic reviews finding positive associations for elasticity and hydration outcomes are a reasonable basis for continued research interest; not yet a basis for routine clinical recommendation

The Script

If a patient comes in asking about some sort of exosome add-on, here are some important points to hit:

• Be honest about current regulatory status: Emphasize that there are currently 0 FDA-approved exosome products for any skin treatment, plus several warnings from the FDA.
• Set realistic expectations for at-home serums: These are regulated as cosmetics and should be relatively safe, but don’t expect dramatic results.
• Use correct wording, not marketing tactics: These exosomes are not “stem cell therapy.” Names and manufacturers of any products given in a med spa or other setting should be verified.
• Encourage patience: Wait for standardized, approved products and the trial data to catch up before building it into routine practice.

[Social Media Mythbusters is intended for dermatology clinicians. Evidence summaries reflect available literature at the time of publication and do not constitute clinical guidelines.]

References

1. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. J Drugs Dermatol. 2025;24(1):12-18. doi:10.36849/JDD.8872

2. US Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (updated through subsequent warning letters, 2023-2026)

3. Liu H, Dong T, Dong C, et al. Plant-derived exosome-like nanovesicles: a novel therapeutic perspective for skin diseases. J Nanobiotechnology. 2025;23(1):640. Published 2025 Oct 10. doi:10.1186/s12951-025-03715-1

4. Alzahrani A, Alghamdi S, Alahmadi M, et al. Exosomes in Skin Rejuvenation: Systematic Review of Anti-Aging Effects and Clinical Applications. Dermatol Pract Concept. 2026;16(1):6462. Published 2026 Jan 30. doi:10.5826/dpc.1601a6462

5. Flores Rodríguez JC, Toledo Avelar LE, Yi K, Merino Arellano R, López Rodríguez JA, Garza Vargas MS. Efficacy of Exosome-Based Therapies for Skin Rejuvenation: A Systematic Review of Human Studies. Cureus. 2026;18(2):e104182. Published 2026 Feb 24. doi:10.7759/cureus.104182

6. Kim HR, Lee SH, Bae WB, et al. Skin Barrier Enhancement and Moisturizing Effects of Exosome Extracts Derived from Pinus densiflora, Zanthoxylum piperitum, and Lagerstroemia indica Plants. Biology (Basel). 2026;15(3):249. Published 2026 Jan 29. doi:10.3390/biology15030249